Chemotherapy in head and neck cancer: Clinical predictors of tolerance and outcomes

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 4, 2011, Pages 380-384

  Kubicek, Gregory J ^a,c   Kimler, Bruce F ^b   Wang, Fen ^b   Reddy, Eashwer K ^b   Girod, Douglas A ^b   Williamson, Steven K ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

capsulation; chemotherapy; head and neck cancer; tolerance

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRESCRIPTION; RADIATION INJURY; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79961168733     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e9c0a2     Document Type: Article

References (16)

1. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000;355:949.
2. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
3. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098. (Pubitemid 37464533)
5. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-1317. (Pubitemid 28175745)
6. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665-4673.
7. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804. (Pubitemid 28277960)
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
9. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952. (Pubitemid 38580197)
10. Homma A, Shirato H, Furuta Y, et al. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J. 2004;10:326-332. (Pubitemid 44403471)
11. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol. 1997;43:29-37. (Pubitemid 27191976)
12. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol. 1992;10:1245-1251.
13. Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol. 2008;47:1513-1518.
14. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-andneck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571-578.
15. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002;24:115-126. (Pubitemid 34111508)
16. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: The importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003;57:693-700. (Pubitemid 37194295)